Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax.
This study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years.
The duration of study participation for each individual subject will be approximately 128 days (4.25 months), including a screening period of approximately 28 days followed by 100 days on study.
| Condition | Intervention | Phase |
|---|---|---|
|
Anthrax |
Biological: BioThrax |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults |
- Immunogenicity as measured by anti-protective antigen (PA) antibody responses using the toxin neutralization antibody assay [ Time Frame: 100 days ] [ Designated as safety issue: No ]Proportion of subjects acheiving a threshold response.
- Immunogenicity, as defined by a predicted vaccine efficacy at defined timepoints. [ Time Frame: 100 days ] [ Designated as safety issue: No ]
| Enrollment: | 200 |
| Study Start Date: | November 2011 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: BioThrax (0.5 mL, on days 0, 14, and 28) |
Biological: BioThrax
BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
Other Name: Anthrax Vaccine Adsorbed (AVA)
|
Detailed Description:
BioThrax® (also called Anthrax Vaccine Adsorbed or AVA) is the only FDA-licensed vaccine for the prevention of anthrax infection. This study will evaluate the immunogenicity of the vaccine using a post-exposure vaccination schedule. Correlations will be drawn to immunogenicity and survival data from animal models to demonstrate that BioThrax® can elicit a protective immune response for PEP.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be between 18 and 65 years of age, inclusive, at the time of enrollment.
- Be in good health as determined by the investigator from medical history and a physical examination.
- If a pre-menopausal female, must be using acceptable methods of birth control.
- Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.
- Be willing and able to return for all visits and blood collections for the duration of the study.
- Have read, understood and signed an informed consent form.
Exclusion Criteria:
- Prior immunization with anthrax vaccine or known exposure to anthrax organisms.
- Intend to enlist in the military during the study.
- Have a known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex.
- Plan to receive experimental products at any time during the study.
- Have received a live vaccine in the 30 days before study entry.
- Plan to receive a live vaccine at any time during the study.
- Have ongoing drug abuse/dependence (including alcohol) issues and/or test positive in a urine drug screen for amphetamines, barbiturates, cocaine or opiates;
- Have received immunosuppressive therapy (including systemic steroids) within 3 months prior to study entry.
- Have a condition known to produce or be associated with immunosuppression.
- Have received cytotoxic therapy in the previous 5 years.
- A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.
Contacts and Locations| United States, Florida | |
| Miami Research Associates | |
| Miami, Florida, United States, 33143 | |
| United States, New York | |
| Rochester Clinical Research | |
| Rochester, New York, United States, 14609 | |
| United States, South Carolina | |
| Coastal Carolina Research Center | |
| Mt. Pleasant, South Carolina, United States, 29464 | |
| United States, Utah | |
| Jean Brown Research | |
| Salt Lake City, Utah, United States, 84124 | |
| Principal Investigator: | Robert Hopkins, MD, MPH, TM | Emergent BioSolutions Inc. |
More Information
No publications provided
| Responsible Party: | Emergent BioSolutions |
| ClinicalTrials.gov Identifier: | NCT01491607 History of Changes |
| Other Study ID Numbers: | EBS.AVA.006, HHSO100200700037C |
| Study First Received: | December 12, 2011 |
| Last Updated: | June 19, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Emergent BioSolutions:
|
post-exposure prophylaxis toxin neutralization assay |
Additional relevant MeSH terms:
|
Anthrax Bacillaceae Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on June 18, 2013